Abstract
1. It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the normal population. 3. There was no tendency for subjects with lung cancer to metabolise debrisoquine more rapidly than non-cancer subjects. 4. It is concluded that debrisoquine metabolic phenotype is not a good predictor of risk of developing lung cancer in the population at large.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / chemically induced
-
Adenocarcinoma / metabolism
-
Aged
-
Aged, 80 and over
-
Carcinoma, Small Cell / chemically induced
-
Carcinoma, Small Cell / metabolism
-
Carcinoma, Squamous Cell / chemically induced
-
Carcinoma, Squamous Cell / metabolism
-
Debrisoquin / analogs & derivatives
-
Debrisoquin / metabolism*
-
Debrisoquin / urine
-
Female
-
Humans
-
Isoquinolines / metabolism*
-
Lung Neoplasms / chemically induced
-
Lung Neoplasms / metabolism*
-
Male
-
Middle Aged
-
Oxidation-Reduction
-
Phenotype
-
Risk
-
Smoking / metabolism
Substances
-
Isoquinolines
-
4-hydroxydebrisoquin
-
Debrisoquin